CITATION REPORT List of articles citing

Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocar

DOI: 10.1158/1078-0432.ccr-14-1269 Clinical Cancer Research, 2014, 20, 5937-5945.

Source: https://exaly.com/paper-pdf/57785469/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper IF	Citations
229	Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. 2015 , 9, 3529-45	101
228	SHH inhibitors for the treatment of medulloblastoma. 2015 , 15, 763-70	30
227	Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer. 2015 , 12, 1289-98	63
226	Efficacy of Hedgehog pathway inhibitors in Basal cell carcinoma. 2015 , 14, 633-41	56
225	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. 2015 , 59, 65-81	98
224	Sleep duration and breast cancer risk in the breast cancer detection demonstration project follow-up cohort: true associations or bias?. 2015 , 112, 1838-9	3
223	Comment on: Elmooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. 2015 , 112, 1838	2
222	Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. 2015 , 75, 2292-304	56
221	Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy. 2015 , 17, e5	56
220	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. 2015 , 33, 4284-92	323
219	Minimal residual disease in cancer therapySmall things make all the difference. 2015 , 21-22, 1-10	19
218	Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation. 2015 , 33, 2893-902	26
217	Cisplatin induces stemness in ovarian cancer. 2016 , 7, 30511-22	49
216	Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. 2016 , 7, 1497-514	55
215	CASTIN: a system for comprehensive analysis of cancer-stromal interactome. 2016 , 17, 899	8
214	Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. 2016 , 7, 487-94	33
213	Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal. 2016 , 6, 115	33

(2016-2016)

212	, 11, e0165496	8
211	Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 6153-6163	45
210	Reduced proliferation and increased apoptosis of the SGC-7901 gastric cancer cell line on exposure to GDC-0449. 2016 , 13, 1434-40	7
209	Nanomedicines Eradicating Cancer Stem-like Cells in Vivo by pH-Triggered Intracellular Cooperative Action of Loaded Drugs. 2016 , 10, 5643-55	56
208	Screening out irrelevant cell-based models of disease. 2016 , 15, 751-769	297
207	Approaches for targeting cancer stem cells drug resistance. 2016 , 11, 1201-1212	23
206	The hedgehog pathway in triple-negative breast cancer. 2016 , 5, 2989-3006	71
205	HER2 expression identifies dynamic functional states within circulating breast cancer cells. 2016 , 537, 102-106	237
204	Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via Hedgehog signaling. 2016 , 14, 1907-14	14
203	Prognostic value of hedgehog signaling pathway in digestive system cancers: A systematic review and meta-analysis. 2016 , 16, 71-9	6
202	Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. 2016 , 17, 1720-1731	91
201	Pancreatic cancer. 2016 , 2, 16022	838
200	Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. 2016 , 16, 249-58	12
199	SHh-Gli1 signaling pathway promotes cell survival by mediating baculoviral IAP repeat-containing 3 (BIRC3) gene in pancreatic cancer cells. 2016 , 37, 9943-50	14
198	A novel therapeutic approach against B-cell non-Hodgkinß lymphoma through co-inhibition of Hedgehog signaling pathway and autophagy. 2016 , 37, 7305-14	7
197	Hedgehog signaling: modulation of cancer properies and tumor mircroenvironment. 2016 , 15, 24	111
196	Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer. 2016 , 13, 1822-32	19
195	Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. 2016 , 381, 259-68	26

194	Nicotine induces self-renewal of pancreatic cancer stem cells via neurotransmitter-driven activation of sonic hedgehog signalling. 2016 , 52, 188-96	25
193	The emerging roles of F-box proteins in pancreatic tumorigenesis. 2016 , 36, 88-94	15
192	Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. 2016 , 20, 341-59	24
191	Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways. 2017 , 79, 411-420	8
190	Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mice. 2017 , 152, 1492-1506.e24	121
189	Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. 2017 , 97, 302-317	24
188	Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. 2017 , 214, 579-596	906
187	Hedgehog Signaling: From Basic Biology to Cancer Therapy. 2017 , 24, 252-280	186
186	Inhibition of the CyclinD1 promoter in response to sonic hedgehog signaling pathway transduction is mediated by Gli1. 2017 , 13, 307-314	13
185	Stromal SPOCK1 supports invasive pancreatic cancer growth. 2017 , 11, 1050-1064	21
184	Tumour tissue transport after intraperitoneal anticancer drug delivery. 2017 , 33, 534-542	21
183	The role of stromal cancer-associated fibroblasts in pancreatic cancer. 2017 , 10, 76	201
182	Medulloblastoma in Adults. 2017 , 917-938	
181	Combination of chemotherapy and cancer stem cell targeting agents: Preclinical and clinical studies. 2017 , 396, 103-109	54
180	The challenge of targeting cancer stem cells to halt metastasis. 2017 , 44, 25-42	117
179	Hedgehog-mesenchyme gene signature identifies bi-modal prognosis in luminal and basal breast cancer sub-types. 2017 , 13, 2615-2624	5
178	Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. 2017 , 16, 2399-2409	19
177	Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. 2017 , 144, 105-118	36

(2018-2017)

176	2017, 46, 973-985	3
175	The Pancreatic Cancer Microenvironment. 2017 , 23, 321-325	85
174	Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol. 2017 , 118, 499-509	9
173	Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. 2017 , 17, 452-460	11
172	Stroma - A Double-Edged Sword in Pancreatic Cancer: A Lesson From Targeting Stroma in Pancreatic Cancer With Hedgehog Signaling Inhibitors. 2018 , 47, 382-389	20
171	Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma. 2018 , 4, 239-255	52
170	Tumor-Stroma IL1🛘RAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. 2018 , 78, 1700-1712	80
169	Randomized trial comparing the Franseen and Fork-tip needles[for EUS-guided fine-needle biopsy sampling of solid[pancreatic mass lesions. 2018, 87, 1432-1438	91
168	Pancreatic Cancer Stem Cells. 2018 , 349-368	
167	Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis. 2018 , 369-382	
166	Stromal Inflammation in Pancreatic Cancer: Mechanisms and Translational Applications. 2018 , 481-508	
166 165	Stromal Inflammation in Pancreatic Cancer: Mechanisms and Translational Applications. 2018, 481-508 Precision Medicine Based on Next-Generation Sequencing and Master Controllers. 2018, 1577-1611	0
		0
165	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. 2018, 1577-1611 Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature. 2018,	o 13
165 164	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. 2018, 1577-1611 Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature. 2018, 97, 275-287 Casticin inhibits the epithelial-mesenchymal transition in ovarian carcinoma via the hedgehog	013777
165 164 163	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. 2018, 1577-1611 Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature. 2018, 97, 275-287 Casticin inhibits the epithelial-mesenchymal transition in ovarian carcinoma via the hedgehog signaling pathway. Oncology Letters, 2018, 15, 4495-4502 Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells.	7
165164163162	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. 2018, 1577-1611 Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature. 2018, 97, 275-287 Casticin inhibits the epithelial-mesenchymal transition in ovarian carcinoma via the hedgehog signaling pathway. Oncology Letters, 2018, 15, 4495-4502 Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells. 2018, 7, Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a	7
165164163162161	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. 2018, 1577-1611 Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature. 2018, 97, 275-287 Casticin inhibits the epithelial-mesenchymal transition in ovarian carcinoma via the hedgehog signaling pathway. Oncology Letters, 2018, 15, 4495-4502 Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells. 2018, 7, Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. 2018, 9, 21613-21627	7 77 29

158	Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. 2018, 10,	10
157	Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer. 2018 , 8,	17
156	Pharmacokinetics and Tissue Transport of Intraperitoneal Chemotherapy. 2018, 27, 477-494	12
155	Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer. 2018 , 315, G27-G35	14
154	Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. 2018, 10,	12
153	The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway. 2018 , 52, 2101-2109	14
152	Hedgehog Signaling Pathway and Autophagy in Cancer. 2018 , 19,	45
151	Strategies of targeting pathological stroma for enhanced antitumor therapies. 2019 , 148, 104401	8
150	Regulating autophagy facilitated therapeutic efficacy of the sonic Hedgehog pathway inhibition on lung adenocarcinoma through GLI2 suppression and ROS production. 2019 , 10, 626	18
149	Multifunctional role of pancreatic stellate cells in pancreatic cancer. 2019 , 2, 10-10	10
148	Obligat: histologische Sicherung vor neoadjuvanter Therapie des Pankreaskarzinoms. 2019 , 25, 653-657	
147	Cancer-associated fibroblasts-heroes or villains?. 2019 , 121, 293-302	89
146	SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer. 2019 , 48, 161-168	11
145	CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. 2019 , 5, 724-741	109
144	Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. 2019 , 8, 10	86
143	Dissecting the molecular landscape of pancreatic cancer: towards a precision medicine approach. 2019 , 4, 113-119	3
142	A Cancer Stem Cell Perspective on Minimal Residual Disease in Solid Malignancies. 2019 , 31-49	1
141	Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties. 2019 , 8,	6

140	Cancer Stem Cell Resistance to Targeted Therapy. 2019 ,	1
139	Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. 2019 , 9, 1102-1123	479
138	Role of Hedgehog Signaling in Breast Cancer: Pathogenesis and Therapeutics. 2019 , 8,	44
137	Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer. 2019, 8,	39
136	Inhibiting Hedgehog: An Update on Pharmacological Compounds and Targeting Strategies. 2019 , 62, 8392-8411	14
135	Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. 2019 , 11,	27
134	Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. 2019, 7,	19
133	The double edge sword of fibrosis in cancer. 2019 , 209, 55-67	65
132	Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non-Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion. 2019 , 21, 482-493	16
131	Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis. 2019 , 156, 2073-2084	27
130	Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer. 2019 , 370, 682-694	12
129	Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy. 2019 , 448, 31-39	33
128	Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives. 2019, 8,	28
127	Reflections on depletion of tumor stroma in pancreatic cancer. 2019 , 1871, 267-272	12
126	Current knowledge on drug resistance and therapeutic approaches to eliminate pancreatic cancer stem cells. 2019 , 69-80	0
125	Stromal biology and therapy in pancreatic cancer: ready for clinical translation?. 2019 , 68, 159-171	151
124	Targeting Cancer Stemness in the Clinic: From Hype to Hope. 2019 , 24, 25-40	223
123	Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. 2019 , 81, 50-69	23

122	Epithelial-Stromal Interactions in Pancreatic Cancer. 2019 , 81, 211-233	18
121	Targeting Hedgehog signaling pathway: Paving the road for cancer therapy. 2019 , 141, 466-480	33
120	Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer Cells. 2019 , 8,	15
119	IL1-Induced JAK/STAT Signaling Is Antagonized by TGFIto Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. 2019 , 9, 282-301	400
118	The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. 2019 , 38, 1764-1777	32
117	Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles. 2019 , 56, 149-167	13
116	Metabolism in the Tumor Microenvironment. 2020 , 4, 17-40	30
115	Phospholipid prodrug conjugates of insoluble chemotherapeutic agents for ultrasound targeted drug delivery. 2020 , 4, 40-56	7
114	Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. 2020 , 122, 498-505	60
113	Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy. 2020 , 43, 121-133	9
112	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. 2020 , 20, 101-109	12
111	Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives. 2020 , 1874, 188444	6
110	Pancreatic Fibroblast Heterogeneity: From Development to Cancer. 2020 , 9,	10
109	Biomarkers for cancer-associated fibroblasts. 2020 , 8, 64	29
108	Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions. 2020 , 12,	10
107	Translational Pancreatic Cancer Research. 2020 ,	1
106	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. 2020 , 20, 1115-1122	6
105	The Role of Smoothened in Cancer. 2020 , 21,	11

(2021-2020)

104	Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. 2020 , 17, 204-232	199
103	Force-exerting perpendicular lateral protrusions in fibroblastic cell contraction. 2020 , 3, 390	9
102	The use of hedgehog antagonists in cancer therapy: a comparison of clinical outcomes and gene expression analyses. 2020 , 21, 873-883	3
101	Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. 2020 , 9,	35
100	Loss of microRNA-21 leads to profound stromal remodeling and short survival in K-Ras-driven mouse models of pancreatic cancer. 2020 , 147, 2265-2278	8
99	Antifibrotic therapy to normalize the tumor microenvironment. 2020 , 18, 207	25
98	Recapitulating pancreatic tumor microenvironment through synergistic use of patient organoids and organ-on-a-chip vasculature. 2020 , 30, 2000545	24
97	Oxidative stress induces monocyte-to-myofibroblast transdifferentiation through p38 in pancreatic ductal adenocarcinoma. 2020 , 10, e41	15
96	Liver Matrix in Benign and Malignant Biliary Tract Disease. 2020 , 40, 282-297	10
95	An evolving paradigm of cancer stem cell hierarchies: therapeutic implications. 2020 , 10, 3083-3098	18
94	OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. <i>Clinical Cancer Research</i> , 2020 , 26, 3420-3430	22
93	Fibroblast Reprogramming in Gastrointestinal Cancer. 2020 , 8, 630	11
92	Microenvironmental Determinants of Pancreatic Cancer. 2020 , 100, 1707-1751	62
91	Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy. 2020 , 19, 1308-1319	18
90	Diversity and Biology of Cancer-Associated Fibroblasts. 2021 , 101, 147-176	103
89	Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast-Driven Nutritional Support and Immunosuppression. 2021 , 11, 446-479	31
88	Stromal Protein-Mediated Immune Regulation in Digestive Cancers. 2021, 13,	5
87	Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. 2021 , 13,	9

86	Palladin isoforms 3 and 4 regulate cancer-associated fibroblast pro-tumor functions in pancreatic ductal adenocarcinoma. 2021 , 11, 3802	4
85	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. 2021 , 13,	14
84	Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment. 2021 ,	10
83	TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment. 2021 , 29, 920-936	8
82	Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression. 2021 , 66, 103315	13
81	Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells. 2021 , 22,	5
80	Hedgehog signaling mechanism and role in cancer. 2021,	15
79	Single-cell advances in stromal-leukocyte interactions in cancer. 2021 , 302, 286-298	2
78	Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. 2021 , 27, 2105-2121	4
77	Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines. 2021 , 13,	10
76	Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer. 2021, 13,	1
75	A birdß eye view of fibroblast heterogeneity: A pan-disease, pan-cancer perspective. 2021 , 302, 299-320	9
74	Immunotherapy in Pancreatic Adenocarcinoma: Beyond "Copy/Paste". <i>Clinical Cancer Research</i> , 2021 , 27, 6287-6297	5
73	Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. 2021 , 9, 655152	11
72	Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells. 2021 , 16, e0254011	О
71	Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. 2021 , 13,	6
70	The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. 2021 , 13,	6
69	Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. 2021 , 39, 1227-1244.e20	32

(2021-2021)

68	New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. 2021 ,	3
67	Metastatic pancreatic cancer: Mechanisms and detection (Review). 2021 , 46,	2
66	gene silencing prevents colorectal cancer progression via suppressing Sonic Hedgehog (SHH) signaling pathway. 2021 , 12, 150-162	2
65	Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2023-2037	54
64	Therapeutic Targeting of Stromal Components. 2020 , 157-168	1
63	Netrin G1 promotes pancreatic tumorigenesis through cancer associated fibroblast driven nutritional support and immunosuppression.	7
62	Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. 2018 , 9, 78-86	41
61	Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. 2016 , 7, 51569-51580	16
60	Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. 2017 , 8, 4399-4409	11
59	MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. 2016 , 7, 16396-408	60
58	Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer. 2015 , 7, 1983-93	21
57	Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. 2016 , 22, 776-89	37
56	Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features. 2015 , 7, 292-302	12
55	Cancer stem cell impact on clinical oncology. 2018 , 10, 183-195	29
54	Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. 2021 , 39, 1531-1547.e10	16
53	The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies. 2021 , 11, 751311	13
52	Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer. 2021 , 37, 109852	1
51	Heterogeneity in Pancreatic Cancer Fibroblasts-TGFlas a Master Regulator?. 2021 , 13,	3

50	Pancreatic Cancer Stem Cells. 2016 , 1-20	
49	Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis. 2017, 1-14	
48	Stromal Inflammation in Pancreatic Cancer: Mechanisms and Translational Applications. 2017, 1-28	
47	Precision Medicine Based on Next Generation Sequencing and Master Controllers. 2018, 1-35	
46	Treatment of Advanced Pancreatic Carcinoma. 2019 , 255-268	
45	Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management. 2019 , 15, 27	1
44	Force-exerting lateral protrusions in fibroblastic cell contraction.	1
43	Single-Cell RNA-Seq Reveals Dynamic Change in Tumor Microenvironment During Pancreatic Ductal Adenocarcinoma Malignant Progression.	
42	The diagnostic yield of specimens obtained from endoscopic ultrasound guided fine needle biopsy of solid masses with the AcquireTM needle. 2020 , 9, 106-110	
41	Cell Lineage Infidelity in PDAC Progression and Therapy Resistance 2021 , 9, 795251	1
40	Potential of PAR-4 as a Therapeutic Target for Pancreatic Cancer. 2021 , 161-170	
39	Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies 2022 , 12, 1030-1060	5
38	Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer 2022 , 14,	1
37	Targeting hedgehog signaling in pancreatic ductal adenocarcinoma 2022, 108107	4
36	Meaningful connections: Interrogating the role of physical fibroblast cell-cell communication in cancer 2022 , 154, 141-168	О
35	Eribulin normalizes pancreatic cancer-associated fibroblasts by simulating TGFIInhibition.	
34	High throughput screen in a co-culture model to uncover therapeutic strategies to potentiate the cancer-inhibiting properties of the tumor-stroma in pancreatic cancer.	
33	Heterogeneous Pancreatic Stellate Cells Are Powerful Contributors to the Malignant Progression of Pancreatic Cancer 2021 , 9, 783617	O

32	Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting 2021 , 22,		4
31	Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets 2022,		4
30	Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancreatic Cancer. 2104594		1
29	Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy?. <i>European Journal of Pharmacology</i> , 2022 , 928, 175087	5.3	1
28	Hedgehog signaling regulates the development and treatment of glioblastoma (Review). <i>Oncology Letters</i> , 2022 , 24,	2.6	
27	Facts and Hopes in Immunotherapy of Pancreatic Cancer. Clinical Cancer Research, OF1-OF12	12.9	3
26	Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. 2022 , 18, e1010315		0
25	The Extracellular Matrix: A Key Accomplice of Cancer Stem Cell Migration, Metastasis Formation, and Drug Resistance in PDAC. 2022 , 14, 3998		2
24	Canonical Hedgehog Pathway and Noncanonical GLI Transcription Factor Activation in Cancer. 2022 , 11, 2523		1
23	Aberrant transcription factors in the cancers of the pancreas. 2022 , 86, 28-45		Ο
23	Aberrant transcription factors in the cancers of the pancreas. 2022 , 86, 28-45 Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. 2022 , 64, 100864		0
	Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in		
22	Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. 2022 , 64, 100864 Increasing cancer permeability by photodynamic priming: from microenvironment to		0
22	Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. 2022, 64, 100864 Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of		0
22 21 20	Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. 2022, 64, 100864 Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.		0 0 2
22 21 20	Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. 2022, 64, 100864 Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies. Targeting Gastric Cancer Stem Cells to Enhance Treatment Response. 2022, 11, 2828		O O 2
22 21 20 19	Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. 2022, 64, 100864 Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies. Targeting Gastric Cancer Stem Cells to Enhance Treatment Response. 2022, 11, 2828 A comprehensive review of pancreatic cancer and its therapeutic challenges. 2022, 14, 7635-7649 Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a		O O 2

14	Targeting the tumor stroma for cancer therapy. 2022 , 21,	3
13	Epithelial and stromal co-evolution and complicity in pancreatic cancer.	O
12	Cancer-Associated Fibroblast Diversity Shapes Tumor Metabolism in Pancreatic Cancer. 2023 , 15, 61	O
11	Eribulin normalizes pancreatic cancer-associated fibroblasts by simulating selected features of TGFIInhibition. 2022 , 22,	O
10	Nanocarriers-Based Targeted Therapies for Pancreatic Cancer and Challenges Ahead. 2022, 129-148	0
9	Strategies for Heating Up Cold Tumors to Boost Immunotherapies. 2023 , 7,	O
8	Cancer-Associated Fibroblasts: Lessons from Pancreatic Cancer. 2023 , 7,	0
7	Challenges and Opportunities Modeling the Dynamic Tumor Matrisome.	O
6	Emerging Roles of Hedgehog Signaling in Cancer Immunity. 2023 , 24, 1321	O
5	Perspective Chapter: Critical Role of Hedgehog in Tumor Microenvironment.	Ο
5 4	Perspective Chapter: Critical Role of Hedgehog in Tumor Microenvironment. Single-cell analysis reveals the COL11A1+ fibroblasts are cancer-specific fibroblasts that promote tumor progression. 14,	0
	Single-cell analysis reveals the COL11A1+ fibroblasts are cancer-specific fibroblasts that promote	
4	Single-cell analysis reveals the COL11A1+ fibroblasts are cancer-specific fibroblasts that promote tumor progression. 14, Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in	O